1,377 results on '"Mori, Masahiro"'
Search Results
2. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial
3. Digital Motor Biomarkers of Cerebellar Ataxia Using an RGB-Depth Camera-Based Motion Analysis System
4. Elevated serum levels of C-terminal agrin fragment in acetylcholine receptor antibody-positive myasthenia gravis
5. Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan
6. Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls
7. Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
8. Health-related quality of life in Japanese patients with multiple sclerosis
9. Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma
10. Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders
11. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study
12. Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody–associated disease
13. Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine
14. Possibility of non-Fickian mixing at concentration interface between stratified suspensions
15. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
16. Markedly upregulated serum semaphorin 4A as a novel activity marker of myasthenia gravis
17. Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients
18. Age-Dependent Changes in Effective Dose in Pediatric Brain CT: Comparisons of Estimation Methods
19. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke
20. Impact of visceral fat on the prognosis of coronavirus disease 2019: an observational cohort study
21. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study
22. Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis
23. Digital Motor Biomarkers of Cerebellar Ataxia Using an RGB-Depth Camera-Based Motion Analysis System
24. THE UNCANNY VALLEY
25. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
26. Soluble CD40 ligand disrupts the blood–brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis
27. Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder
28. Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder
29. Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity
30. Real-time cholesterol sorting in Plasmodium falciparum-erythrocytes as revealed by 3D label-free imaging
31. Age-Dependent Changes in Effective Dose in Pediatric Brain CT: Comparisons of Estimation Methods.
32. Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration
33. Roles of Nectins and Nectin-Like Molecules in the Nervous System
34. Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy
35. Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies
36. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy
37. Immunoglobulin Superfamily Receptors and Adherens Junctions
38. Health-related quality of life in Japanese patients with multiple sclerosis
39. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
40. Lower motor neuron syndrome associated with IgG anti-GM1 antibodies revisited
41. Chronic inflammatory demyelinating polyneuropathy: The spectrum and immunopathogenesis deciphered by electrophysiology and neuroimaging
42. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis
43. Cell-based flow cytometry assay for simultaneous detection of multiple autoantibodies in a single serum sample
44. Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: Evidence of activity-dependent conduction block
45. Retinol palmitate prevents ischemia-induced cell changes in hippocampal neurons through the Notch1 signaling pathway in mice
46. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
47. Recruitment of an Inhibitory Hippocampal Network after Bursting in a Single Granule Cell
48. Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis
49. COVID-19 vaccination: effective utilization of low dead space (LDS) syringes
50. Activity-dependent alteration of the morphology of a hippocampal giant synapse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.